Abstract 4727
Background
Patients with Glioblastoma multiforme (GBM) have a poor prognosis and therapeutic options are scarce after recurrence. Bevacizumab (Bv) is approved for use in this setting with proven benefits in progression-free survival (PFS) but not in overall survival (OS). Arterial hypertension (HT), a well described side effect of Bv, has been proposed as a predictive marker of clinical response in GBM as well as in other neoplasms, though conflicting data is available. This study tried to evaluate the prognostic impact of HT and other factors in recurrent GBM.
Methods
Retrospective cohort of adult patients with recurrent GBM treated with a combination of Bv + Irinotecan (BvI) or Lomustine (BvL) between 01/01/2009 and 31/12/2017. Clinical records were analysed. Bv-induced HT was defined as a single evaluation ≥140/90 mmHg during first 3 months of treatment or the need to initiate or increase dose of antihypertensive drugs. OS and PFS were estimated by Kaplan-Meier method and multivariate analysis according to Cox regression; a significant level of 0.05 was chosen to assess the statistical significance.
Results
120 patients were included with male gender predominance (64.2%) and a median age at Bv onsent of 58.7 (27-78 yo). All patients were treated in first line with surgery (complete resection: 61.7%; partial resection: 38.3%) and Stupp protocol. BvI was used in 70.8% (n = 85) and BvL in 29.2% (n = 35) patients. Bv-induced HT was found in 29% of patients (n = 29) and proteinuria (PU) in 15% (n = 18). Median PFS was 4.4 months (mo) (CI 95% 3.5-5.4) and median OS was 7.8 mo (CI 95% 6.8-87). In multivariate analysis (Table), both HT and PU had an impact in PFS. OS was significantly prolonged in patients with HT and in those without corticosteroids (CCS) at Bv.Table: 389P
| PFS (mo) | HR (CI 95%) | OS (mo) | HR (CI 95%) | ||
|---|---|---|---|---|---|
| HT | Yes | 9.1 | HR 1.825 (1.136-2.931), p = 0.013 | 14 | HR 2.726 (1.325-5.608), p = 0.006 |
| No | 4.1 | 7.8 | |||
| PU | Yes | 6.1 | HR 2.341 (1.282-4.275), p = 0.006 | - | - |
| No | 3.9 | - | |||
| CCS at Bv onset | Yes | - | - | 6.9 | HR 2.022 (1.059-3.860), p = 0.033 |
| No | - | 13.4 |
Conclusions
In recurrent GBM patients treated with Bv combinations, HT was significantly related with prolonged PFS and OS. PU and the need for CCS also showed a significant prognostic impact.
Clinical trial identification
Legal entity responsible for the study
Serviço de Oncologia Médica - Centro Hospitalar de São João, EPE.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract